Apollo Hospitals Saves 41 Yr Old Farmer Who Waited 91 Days for a Heart Transplant with Mitral Chip Implant

Apollo Hospitals, Asia’s foremost and most trusted healthcare group, today announced a successful MitraClip implant on a 41-year-old male farmer who had waited for over three months in different hospitals for a heart transplant. The patient was back on his feet within a few days after the procedure, and might not even need a heart transplant.

Ms. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Group said, “As one of the few hospitals in India accredited to perform the MitraClip procedure, being able to save the life of a patient waiting for a heart transplant gives us the ability to offer hope to many others. Research has shown that using MitraClip as a bridge to heart transplantation is safe and may lead to functional improvements that permit patients to be removed from the transplant list. We are proud to have demonstrated this at Apollo Hospitals through the case of a 41-year-old male patient who was waiting for a heart transplant for over three months. The success of this case has renewed our commitment to taking this cutting edge and revolutionary medical innovation to the people who need it the most.”

Dr. Sai Satish, Senior Interventional Cardiologist, Apollo Hospitals said, “The MitraClip is a globally accepted procedure for patients with heart failure. For three years now we have been performing this procedure on patients and we have seen incredible results in the quality of life they are able to return to. Our experience in this domain has enabled us to achieve many milestones including back-to-back MitraClip implants in four very sick patients in just one day. Today, we are at pole position; 70% of all MitraClips in India to date have been performed at Apollo Hospitals and we are only looking at bigger milestones in the journey ahead.”

India’s first two scientific papers on MitraClip have both been published from Apollo Hopsitals. Dr. Sai Satish is involved in the authorship of the APAC guidelines for MitraClip implants. Asia’s first MitraClip training programme that included theory and four cases over two days was conducted at Apollo Hospitals, cementing its position as a Centre of Excellence in Interventional Cardiology.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”